EasySep™ Human CD138 Positive Selection Kit II

总览

使用EasySep™人CD138正选试剂盒 II，通过免疫磁珠正选可从新鲜或冻存的人骨髓或外周血单个核细胞（MNC）中分离高纯度的CD138+（syndecan-1）细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。

在此EasySep™正选过程中，目的细胞被识别CD138的抗体四聚体复合物和磁珠结合标记，该抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。通过EasySep™磁极分离被标记的目的细胞，只需将非目的细胞倾倒或吸出，而目的细胞则被保留在管中。经磁珠分选后获得的CD138+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD138抗原在正常和恶性浆细胞表面表达（成熟B细胞不表达）。

该产品可替代EasySep™人CD138细胞正选试剂盒 (产品号 #18357 ) 以进行更快的细胞分选。

若需从全血和骨髓中分选CD138+细胞，推荐使用EasySep™人全血及骨髓CD138正选试剂盒（产品号 #17887）。

参加我们免费的CD138+细胞分选在线课程，学习如何处理骨髓样本并分选CD138+浆细胞以提高多发性骨髓瘤FISH检测的灵敏度。您还可以查阅关于CD138+浆细胞分选的常见问题解答（FAQs），了解如何提升FISH检测灵敏度。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD138的抗体四聚体复合物和磁珠结合标记，该抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。通过EasySep™磁极分离被标记的目的细胞，只需将非目的细胞倾倒或吸出，而目的细胞则被保留在管中。经磁珠分选后获得的CD138+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD138抗原在正常和恶性浆细胞表面表达（成熟B细胞不表达）。

该产品可替代EasySep™人CD138细胞正选试剂盒 (产品号 #18357 ) 以进行更快的细胞分选。

若需从全血和骨髓中分选CD138+细胞，推荐使用EasySep™人全血及骨髓CD138正选试剂盒（产品号 #17887）。

参加我们免费的CD138+细胞分选在线课程，学习如何处理骨髓样本并分选CD138+浆细胞以提高多发性骨髓瘤FISH检测的灵敏度。您还可以查阅关于CD138+浆细胞分选的常见问题解答（FAQs），了解如何提升FISH检测灵敏度。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD138的抗体四聚体复合物和磁珠结合标记，该抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。通过EasySep™磁极分离被标记的目的细胞，只需将非目的细胞倾倒或吸出，而目的细胞则被保留在管中。经磁珠分选后获得的CD138+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD138抗原在正常和恶性浆细胞表面表达（成熟B细胞不表达）。

该产品可替代EasySep™人CD138细胞正选试剂盒 (产品号 #18357 ) 以进行更快的细胞分选。

若需从全血和骨髓中分选CD138+细胞，推荐使用EasySep™人全血及骨髓CD138正选试剂盒（产品号 #17887）。

参加我们免费的CD138+细胞分选在线课程，学习如何处理骨髓样本并分选CD138+浆细胞以提高多发性骨髓瘤FISH检测的灵敏度。您还可以查阅关于CD138+浆细胞分选的常见问题解答（FAQs），了解如何提升FISH检测灵敏度。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别CD138的抗体四聚体复合物和磁珠结合标记，该抗体复合物中还含有人Fc受体阻断剂，可最大程度减少非特异性结合。通过EasySep™磁极分离被标记的目的细胞，只需将非目的细胞倾倒或吸出，而目的细胞则被保留在管中。经磁珠分选后获得的CD138+细胞可直接用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。CD138抗原在正常和恶性浆细胞表面表达（成熟B细胞不表达）。

该产品可替代EasySep™人CD138细胞正选试剂盒 (产品号 #18357 ) 以进行更快的细胞分选。

若需从全血和骨髓中分选CD138+细胞，推荐使用EasySep™人全血及骨髓CD138正选试剂盒（产品号 #17887）。

参加我们免费的CD138+细胞分选在线课程，学习如何处理骨髓样本并分选CD138+浆细胞以提高多发性骨髓瘤FISH检测的灵敏度。您还可以查阅关于CD138+浆细胞分选的常见问题解答（FAQs），了解如何提升FISH检测灵敏度。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)

亚型
细胞分选试剂盒

细胞类型
B 细胞，血浆

种属
人

样本来源
Bone Marrow，PBMC

筛选方法
Positive

应用
细胞分选

品牌
EasySep，RoboSep

研究领域
癌症，免疫

查看更多显示更少

实验数据

Figure 1. Typical EasySep™ Human CD138 Positive Selection Profile

Starting with thawed PBMCs spiked with a multiple myeloma cell line, U266, the CD138+ cell content of the isolated fraction typically ranges from 93.0 - 98.2%. In the above example, the purities of the start and final isolated fractions are 9.16% and 94.34%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

RoboSep™ Human CD138 Positive Selection Kit II

Catalog #

17877RF

Lot #

All

Language

English

Document Type

Product Information Sheet

Product Name

EasySep™ Human CD138 Positive Selection Kit II

Catalog #

17877

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

RoboSep™ Human CD138 Positive Selection Kit II

Catalog #

17877RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

RoboSep™ Human CD138 Positive Selection Kit II

Catalog #

17877RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

RoboSep™ Human CD138 Positive Selection Kit II

Catalog #

17877RF

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

EasySep™ Human CD138 Positive Selection Kit II

Catalog #

17877

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

EasySep™ Human CD138 Positive Selection Kit II

Catalog #

17877

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for B Cell Research

Cell Sourcing

Cell Isolation

Cell Expansion

Cell Characterization

相关材料与文献

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. L. Yao et al. Cancer research communications 2022 oct

Abstract

UNLABELLED As part of the Multiple Myeloma Research Foundation (MMRF) immune atlas pilot project, we compared immune cells of multiple myeloma bone marrow samples from 18 patients assessed by single-cell RNA sequencing (scRNA-seq), mass cytometry (CyTOF), and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to understand the concordance of measurements among single-cell techniques. Cell type abundances are relatively consistent across the three approaches, while variations are observed in T cells, macrophages, and monocytes. Concordance and correlation analysis of cell type marker gene expression across different modalities highlighted the importance of choosing cell type marker genes best suited to particular modalities. By integrating data from these three assays, we found International Staging System stage 3 patients exhibited decreased CD4+ T/CD8+ T cells ratio. Moreover, we observed upregulation of RAC2 and PSMB9, in natural killer cells of fast progressors compared with those of nonprogressors, as revealed by both scRNA-seq and CITE-seq RNA measurement. This detailed examination of the immune microenvironment in multiple myeloma using multiple single-cell technologies revealed markers associated with multiple myeloma rapid progression which will be further characterized by the full-scale immune atlas project. SIGNIFICANCE scRNA-seq, CyTOF, and CITE-seq are increasingly used for evaluating cellular heterogeneity. Understanding their concordances is of great interest. To date, this study is the most comprehensive examination of the measurement of the immune microenvironment in multiple myeloma using the three techniques. Moreover, we identified markers predicted to be significantly associated with multiple myeloma rapid progression.

View publication

Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity. K. Ramji et al. Scientific reports 2022 nov

Abstract

Multiple myeloma (MM) remains an incurable malignancy of plasma cells despite constantly evolving therapeutic approaches including various types of immunotherapy. Increased arginase activity has been associated with potent suppression of T-cell immune responses in different types of cancer. Here, we investigated the role of arginase 1 (ARG1) in V$\kappa$*MYC model of MM in mice. ARG1 expression in myeloid cells correlated with tumor progression and was accompanied by a systemic drop in EY-arginine levels. In MM-bearing mice antigen-induced proliferation of adoptively transferred T-cells was strongly suppressed and T-cell proliferation was restored by pharmacological arginase inhibition. Progression of V$\kappa$*MYC tumors was significantly delayed in mice with myeloid-specific ARG1 deletion. Arginase inhibition effectively inhibited tumor progression although it failed to augment anti-myeloma effects of bortezomib. However, arginase inhibitor completely prevented development of bortezomib-induced cardiotoxicity in mice. Altogether, these findings indicate that arginase inhibitors could be further tested as a complementary strategy in multiple myeloma to mitigate adverse cardiac events without compromising antitumor efficacy of proteasome inhibitors.

View publication

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. I. D. Ferguson et al. Nature communications 2022 jul

Abstract

The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma surfaceome at baseline, in drug resistance, and in response to acute drug treatment. We provide a scoring system for surface antigens and identify CCR10 as a promising target in this disease expressed widely on malignant plasma cells. We engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting CCR10 using its natural ligand CCL27. In myeloma models we identify proteins that could serve as markers of resistance to bortezomib and lenalidomide, including CD53, CD10, EVI2B, and CD33. We find that acute lenalidomide treatment increases activity of MUC1-targeting CAR-T cells through antigen upregulation. Finally, we develop a miniaturized surface proteomic protocol for profiling primary plasma cell samples with low inputs. These approaches and datasets may contribute to the biological, therapeutic, and diagnostic understanding of myeloma.

View publication

View All Publications

EasySep™人CD138正选试剂盒 II

产品号 #（选择产品）

产品号 #17877_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

种属	Human
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源	Bone Marrow, PBMC
Selection Method	Positive

EasySep™人CD138正选试剂盒 II

产品号 #（选择产品）

产品号 #17877_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (14)

文献 (14)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台